Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib-Reference-Cited by-同舟云学术

Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Published:2020-02-13 Issue:12 Volume:26 Page:2800-2809
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Alsadhan Anfal^ORCID,Cheung Jean,Gulrajani Michael,Gaglione Erika M.^ORCID,Nierman Pia,Hamdy Ahmed,Izumi Raquel,Bibikova Elena,Patel Priti,Sun Clare^ORCID,Covey Todd,Herman Sarah E.M.,Wiestner Adrian

Funder

Royal Embassy of Saudi Arabia

NHLBI

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study;European Journal of Haematology;2024-02-11

2. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study;The Journal of Clinical Pharmacology;2023-09-29

3. A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects;Clinical and Translational Science;2023-08-16

4. Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models;CPT: Pharmacometrics & Systems Pharmacology;2023-07-26

5. CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy;Clinical Cancer Research;2023-05-09